EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON BLEEDING-TIME, PLATELET NUMBER AND FUNCTION IN CHILDREN WITH END-STAGE RENAL-DISEASE MAINTAINED BY HEMODIALYSIS

被引：31

作者：

FABRIS, F

CORDIANO, I

RANDI, ML

CASONATO, A

MONTINI, G

ZACCHELLO, G

GIROLAMI, A

机构：

[1] Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Padua

[2] Department of Paediatrics, University of Padua Medical School, Padua

来源：

PEDIATRIC NEPHROLOGY | 1991年 / 5卷 / 02期

关键词：

RECOMBINANT HUMAN ERYTHROPOIETIN; CHRONIC RENAL FAILURE; BLEEDING TIME; PLATELET AGGREGATION; THROMBOXANE-B2; PLATELET VOLUME;

D O I：

10.1007/BF01095958

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

We studied platelet number and function in nine anaemic children with end-stage renal disease during a clinical trial with recombinant human erythropoietin (rHu-EPO). All the children showed a correction in both haematocrit and haemoglobin levels which was followed by a significant reduction in bleeding time. We also observed a significant increase in platelet count after both 6 and 12 weeks of therapy; at the same time mean platelet volume decreased and a normal platelet mass was maintained. The mean baseline platelet aggregation response to ADP was normal, but was decreased to collagen (P < 0.05 vs normal control). Platelet production of thromboxane B2 in serum was also lower than normal controls. After correction of anaemia with rHu-EPO, platelet aggregation improved in patients with a decreased baseline response, and mean levels of thromboxane B2 became normal. In conclusion, the treatment with rHu-EPO improved haemostatic balance not only by correcting anaemia, but also by increasing platelet count and function.

引用

页码：225 / 228

页数：4

共 23 条

[11]

Luzzato G., De Franchis G., Fabris F., Gerunda G.E., Girolami A., Increased proportion of giant platelets and platelet distribution width are better indicators of altered platelet homeostasis than mean platelet volume in liver cirrhosis, Folia Haematol (Leipz), 5, pp. 719-726, (1985)

[12]

Remuzzi G., Benigni A., Dodesini P., Patrono C., Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect, J Clin Invest, 71, pp. 762-768, (1983)

[13]

Remuzzi G., Cavenaghi A.E., Mecca G., Donati M.B., De Gaetano G., Prostacyclin-like activity and bleeding in renal failure, Lancet, 2, pp. 1195-1197, (1977)

[14]

Winearls C.G., Oliver D.O., Pippard M.J., Cotes P.M., Effects of human erythropoietin derived from recombinant DNA on the anemia of the patients maintained by chronic haemodialysis, Lancet, 1, pp. 1176-1178, (1986)

[15]

Rabiner S.F., The effect of dialysis on platelet function of Patients with renal failere, Ann N Y Acad Sci, 201, pp. 234-242, (1972)

[16]

van Geet C., Hauglustaine D., Verresen L., Vanrusselt M., Vermylen J., Hemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients, Thromb Haemost, 61, pp. 117-121, (1989)

[17]

Fernandez F., Goudable C., Sie P., Ton-That H., Durand D., Sue J.M., Boneu B., Low haematocrit and prolonged bleeding time in uremic patients: effect of red cell transfusions, Br J Haematol, 59, pp. 139-148, (1985)

[18]

Bloom A., Greaves M., Preston F.E., Brown B., Evidence against a platelet cyclooxygenase defect in uremic subjects on chronic haemodialysis, Br J Haematol, 62, pp. 143-149, (1986)

[19]

Hill J., Levin J., Regulators of thrombopoiesis: their biochemistry and physiology, Blood Cells, 15, pp. 141-166, (1989)

[20]

Thompson C.B., Jakubowski J.A., The pathophysiology and clinical relevance of platelet heterogeneity, Blood, 72, pp. 1-8, (1988)

← 1 2 3 →